Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XW003 Injection in Overweight or Obese Adults
CTR20230745Phase 3Completed
- Sponsor
- Sciwind Biosciences
- Start
- Mar 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of ecnoglutide in Overweight, obesity, sponsored by Sciwind Biosciences. Started Mar 2023; status: completed.
02
Drugs
ecnoglutide
03
Conditions
Overweightobesity
Beyond the preview
Go deeper on CTR20230745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230745.